Israeli molecular diagnostics firm Rosetta Genomics has demonstrated in a study that its microRNA-based biomarkers could be used to help identify different types of renal tumours. This could be important because there are four main subtypes of renal cell carcinoma (RCC): clear cell, ...
Please Login to read the full article.
